New diagnostic technology can reduce mortality in one of the world’s most common infectious diseases
Today, Sciety wants to pay attention to World TB Day, which aims to highlight the extensive health, social and economic consequences of tuberculosis. Tuberculosis is a contagious infectious disease that primarily affects the lungs but also other organs. It is an airborne disease that spreads from one person to another via coughs or sneezes.
One quarter of the world’s population is infected with the bacteria that causes tuberculosis and every year 10 million people fall ill with tuberculosis. More than 4,000 people a day die from the disease, which can be related to the the Ebola outbreak in West Africa in 2013 to 2016. The outbreak killed in total around 11,000 people, an equivalent number of death in tuberculosis in just a few days.
The high mortality is partly due to the fact that today’s diagnostic methods are insufficient. One third of those affected by tuberculosis are undiagnosed or missing from reporting and two thirds of those with antibiotic resistant tuberculosis are misdiagnosed. In the World Health Organization’s (WHO) effort to eradicate tuberculosis, the need for safer, faster and easier diagnostics is a high priority. Early diagnosis and proper treatment are key to reducing the spread of infection and saving lives.
At a global level, approximately SEK 65.3 billion is spent annually to diagnose, prevent and treat tuberculosis. The market for tuberculosis diagnostics is approximately SEK 19.3 billion per year and in 2025 it is expected to reach SEK 36.2 billion.
Sciety will fund a new tuberculosis diagnostic technology
Sciety will soon fund a company that wants to reduce the high mortality rate of tuberculosis. The company develops an easy-to-use and effective DNA-based diagnostic solution. The company’s disposable test can identify the tuberculosis bacterium and detect if the bacterium is resistant to various types of antibiotics. The goal is to provide the test to clinics worldwide, which would allow faster start of correct treatment. The company plans to launch in India, which is the world’s largest market for tuberculosis diagnostics, already in 2021.
Want to learn more about this company?
Register here to get more information about the company and join us for an online interactive presentation with the company’s management.
By combining experience from life science and finance we select promising companies in the industry. We invest own funds in all companies that pass our selection process and offer the investment syndicate to co-invest on the same terms. The syndicate comprises venture capital firms, family offices, and business angels.
Sciety is the leading investor syndicate in the Nordics with an exclusive focus on life science and health tech. Our mission is to help life science innovations to reach their full potential.